Every 10-Q that Royalty Pharma plc (RPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPRX filings page.
Royalty Pharma plc reported total income and other revenues of $674,141 thousand for the quarter and $1,304,717 thousand for the six months ended June 30, 2026, driven mainly by income from financial royalty assets. Six‑month net income attributable to Royalty Pharma plc increased to $312,572 thousand from $271,525 thousand, with basic and diluted EPS of $0.71.
Operating cash flow for the first half rose to $1,446,694 thousand, while $707,587 thousand was used in investing activities, largely for $703,387 thousand of acquisitions of financial royalty assets. Cash and cash equivalents were $811,986 thousand against total debt of $8,961,892 thousand. Financial royalty assets, net, were $17,082,171 thousand. Results reflected a $69,443 thousand impairment on the Tazverik royalty, higher R&D funding expense of $137,641 thousand, and $229,648 thousand of share‑based compensation tied to the 2025 internalization. Shareholder returns included two $0.235 per‑share dividends totaling $209,406 thousand and repurchase of 2.0 million Class A shares for approximately $95.6 million.
Royalty Pharma plc reported higher first-quarter 2026 results, driven by growth in royalty income and strong cash generation. Total income and other revenues reached $630.6 million, up from $568.2 million a year earlier, and net income attributable to Royalty Pharma plc rose to $294.7 million from $239.3 million.
Basic and diluted earnings per Class A share were $0.67, compared with $0.55 in 2025. Operating cash flow was robust at $718.2 million, while the company recorded a $69.4 million non-cash impairment on its Tazverik royalty and recognized $122.3 million of share-based compensation following its 2025 internalization. Cash stood at $586.4 million and total debt principal at $9.18 billion as of March 31, 2026.
Royalty Pharma (RPRX) filed its Q3 2025 10-Q, showing higher top-line but lower profitability as internalization-related expenses flowed through. Total income and other revenues were $609.3 million, up from $564.7 million a year ago, driven by $578.8 million of income from financial royalty assets. Operating income was $427.2 million versus $735.1 million, reflecting a tougher comparison to last year’s favorable provision swing and much higher share-based compensation tied to the May internalization.
Net income attributable to Royalty Pharma plc was $288.2 million ($0.67 diluted EPS) versus $544.0 million ($1.21 diluted EPS) in Q3 2024. Year to date, net cash from operating activities totaled $1.66 billion, while investing included $964.0 million of acquisitions of financial royalty assets and $268.6 million of milestone payments. The company repurchased $1.15 billion of Class A shares year to date and paid $0.66 per share in dividends. The balance sheet added $924.6 million of goodwill and $502.9 million of accrued compensation liabilities from the internalization; long‑term debt was $8.57 billion. As of October 31, 2025, Class A shares outstanding were 427,247,489 and Class B were 149,990,618.